Human antibodies that bind human TNFα

Details Human antibodies that bind human TNFα Human antibodies that bind human TNFα

2007-05-29

2007-05-29

Saunders, David A. (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S145100, C424S158100, C530S388150, C530S388230, C530S389200

Reexamination Certificate

active

09801185

ABSTRACT:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3sec−1or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

REFERENCES:
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6593458 (2003-07-01), Rathjen et al.
patent: 2003/0092059 (2003-05-01), Salfeld et al.
patent: 212 489 (1987-04-01), None
patent: 351 789 (1990-01-01), None
patent: 366 043 (1990-05-01), None
patent: 492 448 (1992-07-01), None
patent: 186 833 (1992-08-01), None
patent: 101 681 (1994-03-01), None
patent: 614 984 (1994-09-01), None
patent: 659 766 (1995-06-01), None
patent: 2 279 077 (1994-12-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 94/29347 (1994-12-01), None
patent: WO 95/23813 (1995-09-01), None
Barbuto, J.A.M., et al. “Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes”, Abstract 2904,Proc. Am. Assoc. Cancer Res., vol. 34, p. 487 (Mar. 1993).
Bendtzen, K. et al., “Auto-Antibodies to IL-1.alpha. and TNF.alpha. in Normal Individuals and in Infectious and Immunoinflammatory Disorders”, inThe Physiological and Pathological Effects of Cytokines, pp. 447-452, Wiley-Liss Inc. (1990).
Boyle, P. et al. “A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-.alpha.”,Cell. Immunol., vol. 152, pp. 556-568 (1993).
Boyle, P. et al. “The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope”,Cell. Immunol., vol. 152, pp. 569-581, (1993).
Chow, A.W. et al. “Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFα, IL-1β, and IL-6 levels in patients with sepsis syndrome”Clinical Research, vol. 42, No. 2 p. 299A (1994).
Cox, J.P.L. et al., “A directory of human germ-line Vxsegments reveals a strong bias in their usage”,Eur. J. Immunol., vol. 24, pp. 827-836 (1994).
Elliott, M.J. et al., “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor .alpha.”,Arthritis&Rheumatism, vol. 36, No. 12, pp. 1681-1690 (1993).
Fomsgaard, A. et al., “Auto-antibodies to Tumor Necrosis Factor .alpha. in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections”,Scand. J. Immunol., vol. 30, pp. 219-223 (1989).
Griffiths, A.D. et al., “Human anti-self antibodies with high specificity from phage display libraries”,EMBO Journal, vol. 12, No. 2, pp. 725-734 (1993).
Huse, W.D. et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda”,Science, vol. 246, pp. 1275-1281 (1989).
Lerner, R.A. et al., “Antibodies without immunization”,Science, vol. 258, pp. 1313-1314 (1992).
Leusch, H-G. et al. “Failure to demonstrate TNF.alpha.-specific autoantibodies in human sera by ELISA and Western blot”,J. Immunol. Methods, vol. 139, pp. 145-147, (1991).
Lewis, et al., “Use of alanine scanning mutagenesis to improve the affinity of an anti-gp120(HIV) antibody”,J. Cell. Biochem. Suppl. vol. 18D, p. 215 (1994).
Marks, J.D. et al., “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”,J. Mol. Biol. , vol. 222, pp. 581-597 (1991).
Moller, A. et al. “Monoclonal antibodies to human tumor necrosis factor .alpha.: in vitro and in vivo application”,Cytokine, vol. 2, No. 3, pp. 162-169 (1990).
Tomlinson, I.M. et al., “the repertoire of human germline VHsequences reveals about fifty groups of VHsegments with different hypervariable loops”,J. Mol. Biol., vol. 227, pp. 776-798 (1992).
Tomlinson, I.M. et al., “The structure repertoire of the human Vkdomain”,EMBO, vol. 14, No. 18, pp. 4628-4638 (1995).
Tracey, K.J. et al., “Tumor necrosis factor: A pleiotropic cytokine and therapuetic target”,Annu. Rev. Med., vol. 45, pp. 491-503 (1994).
Winter, G. et al., “Humanized antibodies”,Immunology Today, vol. 14, No. 6, pp. 243-246 (1993).
Abraham, Edward, et al., “Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients with Sepsis Syndrome,”JAMA, vol. 273(12):934-941 (1995).
Boekstegers, P., et al., “Repeated administration of a F(ab′)2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,”Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).
Brekke, Ole Henrik, et al., “Therapeutic antibodies for human diseases at the dawn of the twenty-first century,”Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).
Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998—Jun. 30, 1999—found online at http://www.surg.med.utoronto.ca/AnnRep/AR98—99/index.html.
Feldman, Marc, et al., “Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?”Annu. Rev. Immunol., vol. 19:163-196 (2001).
Figini, Mariangela, et al., “In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,”J. Mol. Biol., vol. 239:68-78 (1994).
Hawkins, Robert E., et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,”J. Mol Biol., vol. 226:889-896 (1992).
Holler, E., et al., “Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),”Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).
Hoogenboom, Hennie R., et al., “Converting rodent into human antibodies by guided selection,”Antibody Engineering, Oxford University Press, pp. 169-185 (1996).
Kempeni, Joachim, “Update of D2E7: a fully human anti-tumor necrosis factor α monoclonal antibody,”Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).
Low, Nigel N., thesis extract, Cambridge University (1996).
Low, Nigel M., et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,”J. Mol. Biol., vol. 260:359-368 (1996).
Medynski, Dan, “Phage Display. All Dressed Up and Ready to Role,”Bio/Technology, vol. 12:1134-1136 (1994).
Nilsson, Björn, “Antibody engineering,”Current Opinion in Structural Biology, vol. 5:450-456 (1995).
Riechmann, L., et al , “Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity imp

Affiliated with

Also associated with

Rating

Human antibodies that bind human TNFα does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human antibodies that bind human TNFα, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies that bind human TNFα will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3798012